The functional impact of TACI P251L/P205L, a myeloma-associated variant, on NF-kB signalling

Read full text Summarise with VIRAT
Authors: Richard Muyan Chen
Cited by: 0
References: 91

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Multiple myeloma, also known as plasma cell myeloma, is a cancer of plasma cells in the bone marrow. New Zealand has the highest global incidence of myeloma, with higher incidence in Māori and Pacific populations. This study focused on a single nucleotide polymorphism (SNP), rs34562254 in TNFRSF13B, that associates with an increased risk of multiple myeloma and has a high allele frequency in Polynesians. The gene TNFRSF13B encodes the protein transmembrane activator and CAML interactor (TACI), which functions as a B cell receptor and signals through NF-κB pathway. TACI has a long and a short isoform. The rs34562254 variant results in a proline to leucine substitution in TACI; therefore, this variant can also be described as TACI P251L in the long isoform, and P205L in the short isoform. We aimed to explain the association of the TACI P251L/P205L variant and myeloma risk through investigating the functional impact of the variant, specifically in its NF-κB signalling compared to TACI wild type. A luciferase assay was designed and optimised to quantify NF-κB signalling of different forms of TACI by testing their effect on the transcriptional response of an NF-κB reporter construct. In addition, an alternate immunofluorescence method was used to visualise cellular p65 location to measure the NF-κB activities of the different forms of TACI. The key finding of this study was a decreased NF-κB signalling activity of TACI P205L variant in the short isoform, compared to TACI wild type in the short isoform, in both no stimulation and BAFF-stimulated conditions. In the luciferase assay, the NF-κB activity of TACI P205L variant was 51% of the wild type without BAFF, and 29% with BAFF stimulation. For the immunofluorescent p65 localisation assay, the NF-κB activity of P205L variant was 74% of the wild type without BAFF stimulation, and 67% with BAFF stimulation (for the repeat experiment, 52% without BAFF, and 60% with BAFF stimulation). These results suggest a mechanism for the effect of the TACI P205L variant on the increased risk of myeloma. Hypotheses, relating to the role of TACI in B cell development, non canonical NF-κB pathways, and other TACI signalling pathways are discussed.

Fields of Study & Subjects

NF-κB Signaling Pathways Multiple Myeloma Research and Treatments Signaling Pathways in Disease

Publication details

Journal / source
Otago University Research Archive (University of Otago)
Publication date
1 January 2026
Language
EN
Document type
Thesis